Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caio M Rocha Lima

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Gastrointestinal Oncology|March 23, 2018
The <i>nab</i>-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinomaSofia Palacio, Peter J Hosein, Isildinha Reis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateCaio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2014
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereHeloisa P Soares, Soley Bayraktar, Marcelo Blaya, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinomaHoward A Burris, Lee S Rosen, Caio M Rocha-Lima, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Cancer Investigation|October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerCaio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
Journal of Pancreatic Cancer|September 28, 2019
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic CancerVaibhav Sahai, M Wasif Saif, Aparna Kalyan, et al.
BMC Cancer|May 31, 2012
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaPeter J Hosein, Jessica Macintyre, Carolina Kawamura, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Gastrointestinal Oncology|March 23, 2018
The <i>nab</i>-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinomaSofia Palacio, Peter J Hosein, Isildinha Reis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateCaio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2014
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereHeloisa P Soares, Soley Bayraktar, Marcelo Blaya, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Cancer|February 2, 2012
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumorsCaio M Rocha-Lima, Soley Bayraktar, Jessica Macintyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinomaHoward A Burris, Lee S Rosen, Caio M Rocha-Lima, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Cancer Investigation|October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerCaio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
Journal of Pancreatic Cancer|September 28, 2019
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic CancerVaibhav Sahai, M Wasif Saif, Aparna Kalyan, et al.
BMC Cancer|May 31, 2012
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaPeter J Hosein, Jessica Macintyre, Carolina Kawamura, et al.
Pageof 4